

THE biotechnology

SECTOR ON CDNX



CDNX is Canada's public venture exchange for emerging biotechnology companies. It provides a credible and fair marketplace where life science companies can raise the capital needed to develop drugs and biological processes to cure disease and improve the quality of life. For biotechnology investors, CDNX provides an opportunity to get in on the ground floor of emerging companies that are at the forefront of new developments in the medical field.

CDNX AND BIOTECHNOLOGY COMPANIES

CDNX-listed biotechnology companies are pioneering the use of technology to create new life-saving and life-enhancing materials and processes. These companies are actively developing a broad range of sophisticated technologies and processes tackling a range of diseases, such as cancer, AIDS and heart disease. Listed companies also work with universities and scientists from across the country to bring their ideas and concepts out of the laboratories and into the commercial markets.

SECTOR PROFILE

There are three leading biotechnology subsectors raising money in Canada's public markets:

- Biopharmaceuticals: Developing new drugs and cures for diseases.
- Biomedical Diagnostics: Developing information technologies that will assist in research and development of drugs and biological processes.
- Medical Products: Building devices to help in the treatment and detection of disease.

RAISING CAPITAL ON CDNX

The heavy emphasis on research and development means biotech firms need a steady influx of capital. That's where CDNX can help. Technology financings, which include biotech, totalled \$1.196 billion last year. More than \$1.1 billion came from private placements, while \$54 million from initial public offerings and \$22 million from public offerings. Total market capitalization for technology companies trading on CDNX is \$4.5 billion.

WHY CDNX?

- CDNX attracts broad investor participation through a national public venture market.
- CDNX has a proven record of financing success for biotechnology firms. Technology companies listed on CDNX, including biotech, raised almost \$1.2 billion in equity financings in 2000.
- A key measure of CDNX's success is the number of emerging companies that graduate to a senior exchange. In 2000, CDNX-listed companies accounted for 38 per cent of the TSE's new listings.
- CDNX maintains leading edge trading systems to ensure market fairness, integrity and transparency.
- The CDNX Web site is the online destination for disclosure of emerging biotechnology companies. InfoCDNX™ provides investors with more than 50 pages of disclosure on each listed company, allowing them to make informed investment decisions.

SECTOR SNAPSHOT

The top three biotechnology performers on CDNX experienced a share price increase of 187 per cent on average in 2000. Three recent biotechnology graduates saw their market cap rise 620 per cent on average in the year prior to moving to a senior exchange.

The CDNX biotechnology sector features companies at the forefront of research and development. They have raised millions of dollars in private and public venture capital to develop and license products and help finance research conducted by Canada's top scientists.

TM Bioscience Corporation (TMC)

Based in Toronto, TM Bioscience has developed two key DNA-based technologies, HybAssist and Signal Assist. TM's technologies have applications for biochip, diagnostics and genomic analysis. TM's technology is designed to expand the ability of biochips to simultaneously perform hundreds of thousands of biochemical analyses. The company licenses its technology on a non-exclusive basis and is currently developing a customized

the **biotechnology** sector on CDNX

biochip solution for Luminex Corporation. The company has its own biochip development program and recently completed its first prototype. TM Bioscience Corp.'s share price rose 207 per cent from Jan. 1 to Dec. 29, 2000.

Medicure Inc. (MPH)

Medicure, a Winnipeg-based biopharmaceutical company, focuses on developing new cardiovascular therapeutics. Its lead compound, MC-1, is based upon discoveries by Dr. Naranjan Dhalla of the Institute of Cardiovascular Sciences and the Department of Physiology at the University of Manitoba. MC-1, a natural compound, demonstrated a therapeutic value in clinical testing for cardiovascular disorders, such as congestive heart failure, angina and arrhythmia. Medicure's share price rose 99 per cent from Jan. 1 to Dec. 29, 2000

CDNX BIOTECHNOLOGY GRADUATES


CDNX provides a stepping stone for biotechnology companies that are ready to graduate to a senior exchange. Some of our recent graduates experienced tremendous growth in market cap and share price before their move to a senior exchange.

- Isotechnika Inc: Market cap at graduation was \$121 million, a 285 per cent rise in the year prior to graduation. Its share price experienced 157 per cent growth during the same period.
- Procyon Biopharma Inc: Market cap at graduation was \$97 million, a 1,443 per cent rise in the year prior to graduation. During the same period, its share price increased 650 per cent.
- Nortran Pharmaceuticals Inc: Market cap at graduation was \$60 million, a 135 per cent increase in the year prior to graduation. Its share price experienced 63 per cent growth for the year.

TECHNOLOGY EQUITY FINANCINGS

(including biotechnology and information technology companies)

YEAR 2000 FINANCINGS	Proceeds	Number of Transactions
Initial Public Offerings	\$54 million	9
Private Placements	\$1,120 million	331
Public Offerings	\$22 million	10
Total	\$1,196 million	350

YEAR 2000 INDEX PERFORMANCE**MORE INFORMATION**

Discover how CDNX can provide biotechnology companies with an opportunity to grow. Call a CDNX Business Development Executive in your region today for more information.

CALGARY

(403) 974-7400

1-877-884-CDNX (2369)

TORONTO

(416) 367-2369

1-877-421-CDNX (2369)

VANCOUVER

(604) 689-3334

1-877-883-CDNX (2369)

WINNIPEG

(204) 927-2369

1-877-422-CDNX (2369)

WWW.CDNX.COM

information@cdnx.com